Valuation — not yet established
No valuation for TORL BioTherapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($454.3M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for TORL BioTherapeutics
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Apr 2024 | Later Stage VC (Series B2) | $158.3M | ▮ | ▮ |
How TORL BioTherapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For TORL BioTherapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has TORL BioTherapeutics raised?
- TORL BioTherapeutics has raised $454.3M in total funding across 1 recorded rounds.
- When did TORL BioTherapeutics last raise?
- TORL BioTherapeutics last raised in Apr 2024 (Later Stage VC (Series B2)), raising $158.3M.